The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.41
Bid: 1.41
Ask: 1.45
Change: -0.02 (-1.40%)
Spread: 0.04 (2.837%)
Open: 1.41
High: 1.41
Low: 1.41
Prev. Close: 1.43
RTW Live PriceLast checked at -
RTW Venture is an Investment Trust

To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Publication of Circular

14 Jul 2021 07:00

RNS Number : 1313F
RTW Venture Fund Limited
14 July 2021
 

LEI: 549300Q7EXQQH6KF7Z84

14 July 2021

RTW Venture Fund Limited

Intention to apply for admission of Ordinary Shares to listing on the Premium Segment of the Main Market, Publication of Circular and Notice of Extraordinary General Meeting

Further to its announcement on 29 April 2021, RTW Venture Fund Limited (the "Company" or "RTW Venture Fund") announces its intention to apply for admission of its ordinary shares (the "Ordinary Shares") to listing on the Premium Segment of the Official List and the transfer of the admission to trading of the Ordinary Shares from the Specialist Fund Segment to the Premium Segment of the London Stock Exchange plc's Main Market (the "Admission"), subject to the passing of a special resolution to be proposed at an extraordinary general meeting of the Company to be held at 1st Floor, Royal Chambers, St. Julian's Avenue, St Peter Port, Guernsey, GY1 3JX at 3 p.m. (London time) on 30 July 2021 (the "Extraordinary General Meeting").

A notice of the Extraordinary General Meeting is contained in the shareholder circular (the "Circular") published today on the Company's website at www.rtwfunds.com/venture-fund. In addition, a copy of the Circular has been submitted to the National Storage Mechanism and will shortly be available for viewing online at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

As described more fully in the Circular, in order to be eligible for Admission and to comply with the Listing Rules, the Company must, among other things, amend its articles of incorporation (including to make certain revisions to its current shareholder voting structure) and adopt a written investment policy. The Company is also seeking the approval of Shareholders to a waiver granted by the Takeover Panel of the obligations under Rule 9 of the Takeover Code, as described more fully in the Circular. Shareholders are advised to read the whole of the Circular with care.

The Company believes that the Premium Segment of the Main Market is the most appropriate platform for the continued growth of the Company, as the transition is expected to increase the Company's profile, broaden its shareholder register and facilitate the Company's eligibility for inclusion in the FTSE UK Index Series.

Working Capital

The Company is of the opinion that the working capital available to the Company is sufficient for its present requirements, that is for at least the next 12 months from the date of this announcement.

For Further Information

RTW Investments, LP +1 (646) 343 9280Stephanie Sirota, Chief Business Officer

Alexandra Taracanova, PhD, Director of Investor Relations

Julia Enright, Senior Business Development Associate

 

J.P. Morgan Cazenove +44 (0)20 7742 4000

William Simmonds / Jérémie Birnbaum (Corporate Finance)

James Bouverat / Liam MacDonald-Raggett (Sales)

 

Barclays +44 (0)20 7623 2323

Tom Swerling

Andrew Tusa

 

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

Capitalised terms used but not defined in this announcement will have the same meaning as set out in the Circular unless the context otherwise requires.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOGSFLFMDEFSESW
Date   Source Headline
18th Jun 20214:40 pmRNSSecond Price Monitoring Extn
18th Jun 20214:35 pmRNSPrice Monitoring Extension
16th Jun 20217:00 amRNSIssue of Equity
15th Jun 202112:05 pmRNSNew Investment in Umoja Biopharma
14th Jun 20212:32 pmRNSAnnouncement of Share Issuance
14th Jun 20217:00 amRNSNet Asset Value(s)
9th Jun 202112:05 pmRNSNew Investment in Alcyone Therapeutics
2nd Jun 20217:00 amRNSNotice of AGM
26th May 20211:05 pmRNSAdditional Investment in Portfolio Company
20th May 20218:05 amRNSNew Investment in Numab Therapeutics
14th May 20217:00 amRNSNet Asset Value(s)
29th Apr 20217:00 amRNSAnnual Financial Report
28th Apr 20217:00 amRNSQuarterly Update
19th Apr 20217:00 amRNSPortfolio Company Update: Biomea IPO
15th Apr 20217:00 amRNSNet Asset Value(s)
1st Apr 20217:05 amRNSTotal Voting Rights
1st Apr 20217:00 amRNSNotice of Annual Report
30th Mar 20211:00 pmRNSNew Investment in Pyxis Oncology
17th Mar 20217:00 amRNSIssue of Equity
15th Mar 20217:01 amRNSAnnouncement of Share Issuance
15th Mar 20217:00 amRNSPortfolio Company Update: Prometheus IPO
12th Mar 202112:30 pmRNSNew Investment in Monte Rosa Therapeutics
12th Mar 20217:00 amRNSNet Asset Value(s)
9th Mar 20211:45 pmRNSNew Investment in Ventyx Biosciences
9th Mar 202112:45 pmRNSNew Investment in Visus Therapeutics
1st Mar 20211:00 pmRNSNew Investment in Tenaya Therapeutics
1st Mar 20217:00 amRNSTotal Voting Rights
26th Feb 20211:15 pmRNSNew Investment in Artiva Biotherapeutics
18th Feb 20217:00 amRNSIssue of Equity
15th Feb 20214:10 pmRNSAnnouncement of Share Issuance
15th Feb 20217:00 amRNSNet Asset Value(s)
8th Feb 20217:00 amRNSPortfolio Company Update: Immunocore IPO
5th Feb 20217:00 amRNSPortfolio Company Update: Landos IPO
1st Feb 20217:00 amRNSChange of Administrator and Company Secretary
1st Feb 20217:00 amRNSTotal Voting Rights
25th Jan 202110:04 amRNSDirector/PDMR Shareholding
22nd Jan 20217:00 amRNSQuarterly Update
19th Jan 20216:11 pmRNSIssue of Equity
15th Jan 20213:39 pmRNSAnnouncement of Share Issuance
15th Jan 20217:00 amRNSNet Asset Value
11th Jan 202112:22 pmRNSAdditional Investment in Portfolio Company
6th Jan 20213:30 pmRNSNew Investment in Biomea Fusion
29th Dec 202010:16 amRNSDirector/PDMR Shareholding
24th Dec 20208:35 amRNSDirector/PDMR Shareholding
23rd Dec 20209:07 amRNSDirector/PDMR Shareholding
14th Dec 20207:00 amRNSNet Asset Value(s)
10th Dec 20207:00 amRNSTransformational Update from Largest Holding
8th Dec 20208:03 amRNSNew Investment in Nuance Pharma
1st Dec 20207:00 amRNSTotal Voting Rights
16th Nov 20205:59 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.